Roche posts new data backing Actemra for RA

Roche has racked up more late-stage data backing Actemra as a new therapy for rheumatoid arthritis. Researchers say their fifth Phase III trial demonstrated that the therapy inhibited structural damage to joints. And physical function was improved in patients after a year of treatment.

Actemra is widely viewed as one of the three most important late-stage RA drugs in the global pipeline. The wave of late-stage therapies includes Cimzia (certolizumab) and golimumbab, both angling for near-term FDA approvals in the hope of joining the group of anti-TNF therapies on the market. Actemra (tocilizumab) is in a new, non-TNF category that is an odds on favorite to gain approval as a second- or third-line treatment.

- here's Roche's release
- read the AFX report

Related Articles:
Roche seeks FDA approval of RA drug Actemra
Roche sees positive late-stage data on Actemra
New data on Actemra
Chugai seeks Actemra approval

Suggested Articles

The CTAD presentation cleared up some questions about the dataset without delivering a telling blow for either side of the debate.

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.